NEW YORK (GenomeWeb News) – BG Medicine has completed a public offering of 6 million shares of its common stock, raising net proceeds of around $12.8 million.

The Waltham, Mass.-based cardiovascular diagnostics firm said that the underwriters of the offering also exercised their option to purchase 900,000 additional shares. The offering, which was priced at $2 per share, was launched last week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.